Topics:
Radiation Oncology • Palliation • Genitourinary Cancers • Stereotactic Body Radiotherapy • Prostate Cancer • Medical Oncology
When should SBRT be offered to oligometastatic bone disease in a patient with prostate cancer?
What factors should be considered with offering SBRT to oligometastatic bone disease in prostate cancer patients? Should this been done off of a protocol?
Answer from: Radiation Oncologist at Academic Institution
Recently a multi-institutional analysis set standards for use in prospective assessment of SBRT for use in men with > 1 bone metastasis and up to 3 (data shown below). The Rx was well tolerated and local control was significantly improved if a BED > 100 Gy was utilized. At this time this appr...
Sign in or Register to read more
Answer from: Radiation Oncologist at Academic Institution
SBRT for prostate cancer in the asymptomatic setting in order to improve survival or progression-free survival should be considered an unproven but potentially useful approach. Note that NRG Oncology-RTOG is testing SBRT prospectively.
Trial BR001 is a phase I trial assessing the safety of SB...